About us

Our vision

Scientific development in the 20th century has led to significant improvements in society, however problems related to energy resources, the environment, food, and other global issues, persist. What is necessary to solve such major issues? One possible approach is the design of new materials, incorporating the smallest living unit, the cell. Cells are minute systems that produce and convert materials and energy in ways that we are unable to replicate artificially. However, conventional scientific technology has yet to enable the fully utilization of the potential of cells. Here, we make a contribution to solving global issues by engineering platforms which fully utilize the unique abilities of cells.

Our technology

Cell fiber has been developed as a basic technology to handle cells in engineering applications. Fiber-shaped cell clusters can be handled as standardized fibrous components to construct various structures using living cells. We use this technology platform to drive innovation in a wide range of areas, such as medical care, drug development, food production, and bioremediation.


Company name CellFiber Co., Ltd.
Foundation April 1st,2015
Headquarters 216 UT South Clinical Research Building, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-8485, JAPAN
Products and services Cell-laden soft materials


Board Members


Yu Yanagisawa, Ph.D.(Chemistry)

Yu Yanagisawa received his PhD in Chemical and Biomolecular Engineering, Graduate School of Engineering, The University of Tokyo. During his studies, he conducted research on functional polymer materials in Takuzo Aida’s laboratory. He joined CellFiber in February 2018, became a director in May of the same year, and assumed the position of representative director in June 2019. Immediately after joining the company, he has been serving as a principal investigator in projects sponsored by AMED, NEDO, etc., and has been leading the business of CellFiber.

Aki Adachi M.A.(Biology)

Aki Adachi received her master’s degree from Graduate School of Arts and Sciences, the University of Tokyo (Shoji Takeuchi Laboratory, Institute of Industrial Science). After working for a private company for several years, she was appointed as the research promoter of the JST ERATO Takeuchi Bio Integration Project. In April 2015, together with Takeuchi, Okitsu, and Onoe, she established CellFiber Co., Ltd. based on the cell fiber technology that was the result of the ERATO project, and became the representative director. Currently, she is responsible for the development of internal and external business infrastructure and serves as the representative with Yanagisawa.

Hidetoshi Hoshiya, PhD FRSA MRSB (Regenerative Medicine)

After receiving a Ph.D. in regenerative medicine from Tottori University (Japan), he engaged in research at Tottori University, San Raffaele Scientific Institute (Italy), University College London, and Queen Mary University of London (UK). Since 2015, as the manager for the Asian and Oceanian territory, he developed, refined, and implemented the strategy of the Cell and Gene Therapy Catapult, an organization established by the UK government for the industrialization of regenerative medicine, including gene and cell therapy. In November 2019, he became an independent consultant for Start-up, Non-profit, Large pharmaceutical companies in Europe and Asia such as France, UK, and Japan. In December 2020, he was appointed to the board of CellFiber. He has over 15 years of experience in regenerative medicine, cell and gene therapy field.

Hiroaki Onoe, Ph.D.(Mechanical Engineering)

Hiroaki Onoe received his PhD in Information Science and Engineering from the University of Tokyo, and had been an assistant professor in Shoji Takeuchi’s lab since April 2009, where he developed cell fiber technology as an assistant researcher and group leader of the ERATO Takeuchi Project. He started his career as an independent PI in the Faculty of Science and Technology at Keio University in April 2014, and has also served as a Board Director of CellFiber since April 2016. In April 2017 he was awarded the Young Scientist Prize of the Commendation for Science and Technology by the Minister of Education, Culture, Sports, Science and Technology for his research on in vitro tissue formation including cell fibers.

Yoshinobu Osaka

After joining Mitsubishi UFJ Bank, he was in charge of large corporate sales and M&A finance. In April 2016, he was appointed as a Specially Appointed Researcher in Shoji Takeuchi’s laboratory, and was selected for the JST ACCEL Program, becoming JST ACCEL Program Manager in August 2016. He also serves as President and Representative Director of Glocalink, Inc. He received his B.A. from the Graduate School of Business Administration, Keio University.



Shoji Takeuchi (Mechanical Engineering)

Professor ,The University of Tokyo
Website: http://www.hybrid.iis.u-tokyo.ac.jp/


Teru Okitsu (Medical Science)

Specially-appointed professor, The University of Tokyo



Nicholas Gaddum

Detailed profile >>

Yukihiro Maru PhD

Group CEO of Leave a Nest Co., Ltd.

Grants & Awards

Sep 17, 2016 TECHPLAN DEMO DAY 3rd Biotech Grand Prix Yanmar Prize and Suntory Prize
Jan 31, 2017 New Technology Development Foundation “98th (2nd round in 2015) New Technology Development Grant” Selected
Jun 19, 2017 Excellence Award, BRAVE Acceleration Program Pitch Contest
Jul 29, 2017 Subsidy for supporting new development of manufacturing, commerce, and service adopted
Feb 9, 2018 Mitsubishi UFJ Technology Development Foundation “FY2017 2nd R&D Subsidy Project” Selected
Mar 2, 2018 Real Tech Venture of the Year Award
Apr 3, 2018 AMED “Development of Basic Technology for Drug Discovery to Realize Next-generation Treatment and Diagnosis” adopted
Jan 11, 2019 Selected for seed slot in “J-TECH STARTUP 2018
Sep 4, 2019 Winner, ICC Summit KYOTO 2019
Feb 5, 2020 Tokyo Business Design Award 2019 Grand Prize and Theme Award
Feb 2020 Selected for “Next Generation Innovation Creation Project 2020” by Tokyo Metropolitan Government and Tokyo Metropolitan Small and Medium Enterprise Promotion Corporation